Business in brief
THE REGION Alkermes Inc. said it agreed to license its antialcoholism drug Vivitrex to Cephalon Inc. for $160 million and possible additional payments. The Cambridge company's drug has not been approved by the Food and Drug Administration, but has been granted priority review status after a study in April showed alcoholics are more likely to stay on the treatment, which ... (Full article: 526 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
